Pharma Max
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pharma Max - overview
Established
2010
Location
Taizhou, Jiangsu, China
Primary Industry
Biotechnology
About
Based in Jiangsu, China and founded in 2010, Pharma Max is a developer of oronasal drugs, focusing on the research and development, production and sales of new drugs and medical devices. In September 2021, the company completed series B+ funding from China Capital Management, Shanghai Kangcheng Investment Management and Chongning Capital. The company has established a research and development and production platform for liquid preparations, solid preparations, microspheres and liposomes. The founder, chairman of board and president Dr.
Zhijun Jiang, he has been engaged in bio-pharmaceutical innovation research for more than 30 years, he served as vice president of research and development and operation of Teva. The company's medical device products Bi Min Ling, Sai Li Ping, Gan Qing have been approved for listing. The latest funding will be used to accelerate the research and development of respiratory preparations, mental sustained-release preparations, microsphere preparations and liposomes, as well as the construction of GMP workshop.
Current Investors
Hanfor Capital, Efung Capital, Shenzhen Hongshi Capital Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.pharmamaxcorp.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.